
Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19.

Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19.

COVID-19 has only magnified well known flaws of our healthcare system. An extension of Medicare is the affordable solution, writes Bruno Delagneau, and pharma needs to start planning for this to minimize its impact on US revenues.

Dr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.

W2O, today announced findings from a research study on consumer attitudes toward data privacy, specifically personal health data.

How “Contractual Genericization” could revitalize pharma and reframe the public conversation.

IQVIA has announced the launch of OCE Optimizer, which will look to help life sciences companies reach HCPs more effectively.



Gilead's pricing of COVID drug remdesivir is a reminder of pharma's tenuous path forward as it seeks a more holistic image makeover.









While scientists are striving to discover and produce safe and effective vaccines to halt the coronovirus outbreak, anti-vacciners are revving up misinformation campaigns.


Investors welcome biopharma sector initiative.




Welcome to the new look and branding of Pharmaceutical Executive-reimagined to better reflect you, our audience, and expand on the content you've long trusted us to deliver.




